Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma by Massi, Daniela et al.
www.elsevier.com/locate/humpathExpression of protease-activated receptors 1 and 2 in
melanocytic nevi and malignant melanomaBDaniela Massi MDa,1, Antonella Naldini PhDb,1, Camilla Ardinghi PhDb,
Fabio Carraro MD, PhDb, Alessandro Franchi MDa, Milena Paglierani PhDa,
Francesca Tarantini MDc, Sheyda Ketabchi MDa, Giuseppe Cirino MDd,
Morley D. Hollenberg MDe, Pierangelo Geppetti MDc, Marco Santucci MDa,*aDepartment of Human Pathology and Oncology, University of Florence, 50134 Florence, Italy
bDepartment of Physiology, University of Siena, 53100 Siena, Italy
cDepartment of Critical Care Medicine and Surgery, University of Florence, 50139 Florence, Italy
dDepartment of Experimental Pharmacology, University of Naples, 80131 Naples, Italy
eDepartment of Pharmacology and Therapeutics, University of Calgary, T2N 4N1 Calgary, Alberta, Canada
Received 8 March 2005; accepted 18 April 20050046-8177/$ – see front matter D 2005
doi:10.1016/j.humpath.2005.04.008
B This study was financially support
Fondazione MPS, Siena, Italy to A. N.
T Corresponding author. Dipartimen
E-mail address: marco.santucci@uni










assaySummary Protease-activated receptors (PARs) are members of the G protein–coupled receptor
superfamily that are activated by the proteolytic cleavage of their amino terminal domain. PAR-1
activation by thrombin results in several biologic effects, including platelet adhesion to other cells or
extracellular matrix, fibroblast, and endothelial cell growth, whereas PAR-2, activated by trypsin, has
mainly a proinflammmatory and angiogenetic role. PAR-1 and PAR-2 modulate cell proliferation in
physiopathologic cell invasion processes, suggesting that they may play a role in the setting of cancer
growth and metastasis. Here, we have investigated the expression of PAR-1 and PAR-2 proteins by
immunohistochemistry in a series of benign and malignant melanocytic lesions: 20 melanocytic lesions
(10 common melanocytic nevi and 10 atypical or bdysplasticQ melanocytic nevi) and 50 melanomas
(10 in situ melanomas, 10 melanomas T1, 10 melanomas T2, 10 melanomas T3 to T4, and 10 metastatic
melanomas). PAR-1 was significantly overexpressed in atypical nevi and melanomas in comparison
with common melanocytic nevi. PAR-2 was strongly and diffusely expressed by immunohistochemistry
in all melanocytic lesions, with no statistically significant differences between nevi and melanomas.
Because we found a differential expression in PAR-1 protein, but not in PAR-2, we next investigated the
expression of PAR-1 messenger RNA (mRNA) by ribonuclease protection assay in paraffin-embedded
tissues using a paraffin block RNA isolation procedure. Similarly to immunohistochemical results, PAR-
1 mRNA expression was significantly higher in atypical nevi and melanomas in comparison with
common nevi and controls. Overexpression of PAR-1 in atypical nevi and melanomas supports a role forHuman Pathology (2005) 36, 676–685Elsevier Inc. All rights reserved.
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PARs in melanocytic neoplasia 677PAR-1 in the initial phases of melanoma development as well as in tumor progression and metastasis.
Conversely, the significance of PAR-2 up-regulation in both benign and malignant melanocytic lesions
requires further research.
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Recently, there has been considerable interest in under-
standing the biologic significance of protease-activated
receptors (PARs) in physiological and pathological con-
ditions, including neoplastic diseases [1,2]. PARs constitute
a family of G protein–coupled receptors that show a unique
mechanism of activation being enzymatically activated by
serine proteases through cleavage of their amino terminal
domain. So far, 4 PARs have been cloned, PAR-1 and PAR-
3, which are activated by thrombin; PAR-4, which is
activated by thrombin and trypsin; and PAR-2, which is
activated by trypsin, mast cell tryptase, and coagulation
factors [3-7]. PARs are expressed in several tissues by a
variety of cells, and their activation is implicated in
numerous biologic effects, including coagulation, inflam-
mation, mitogenesis, and cell proliferation [1,2,8].
There is emerging evidence that PAR-1 modulates cell
proliferation and motility in physiopathologic cell invasion
processes, suggesting that it plays a role in the setting of
cancer growth and metastasis [9-13]. Indeed, overexpression
of PAR-1 has been detected in numerous human cancers,
including colon [14,15], laryngeal [16], breast [10], pancre-
atic [17,18], and oral cavity carcinomas [19]. Of interest, an
up-regulation of PAR-1 and PAR-2 has been demonstrated
in stromal fibroblasts surrounding neoplastic aggregates in
human malignant tissues [20]. In cutaneous melanomas, it
has been recently shown that loss of expression of the
transcription factor activator protein 2a correlates with
overexpression of PAR-1, which in turn contributes to the
acquisition of a malignant phenotype [21]. Less is known
concerning the role of PAR-2 in cell growth, although it may
also contribute to tumor development and metastasis by
stimulating proliferation of neoplastic cells [22]. More
recently, it has been reported that both PAR-1 and PAR-2
contribute to tumor cell motility and metastasis [23].
In the development of malignant melanoma, the critical
steps of tumor progression were originally postulated as
follows: from benign common melanocytic nevi, to atypical,
bdysplasticQ nevi, to early radial growth phase melanomas
(incapable of metastasis), to vertical growth phase invasive
melanomas with competence for metastasis to metastatic
melanomas [24]. Although it has been suggested that such
stepwise melanocytic tumor progression may reflect distinct
gene expression patterns and messenger RNA (mRNA)
profiles, the exact molecular pathogenetic events underlying
the transition from normal melanocytes into various forms
of melanocytic nevi and melanomas are not fully understood
[25-27]. Great attention has been recently focused on theidentification of markers of tumor progression, including
growth factors, cell surface antigens, extracellular matrix
proteins, and angiogenetic factors, which are differently
expressed in common benign nevi, bdysplastic nevi,Q and in
situ, radial, vertical, and metastatic phases of melanomas.
However, data on PAR-1 and PAR-2 activity in situ in
benign melanocytic nevi, atypical nevi, and human mela-
noma tissue samples are not available.
To define the possible role of PAR-1 and PAR-2 in
melanocytic tumor progression, we evaluated PAR-1 and
PAR-2 immunohistochemical expression in benign and
malignant melanocytic lesions. Because we found a
differential expression in PAR-1 protein, but not in PAR-2
protein, in melanocytic nevi and melanomas, we next sought
to confirm these results at mRNA level through analysis of
PAR-1 expression by ribonuclease protection assay (RPA)
applied to selected archival formalin-fixed paraffin-embed-
ded tissue samples of the same series.2. Materials and methods
2.1. Specimen selection
The study series included 10 cutaneous common
melanocytic nevi; 10 atypical or dysplastic nevi, 10 cutane-
ous melanomas in situ, 10 pT1 invasive melanomas, 10 pT2
invasive melanomas, 10 pT3 and pT4 invasive melanomas,
and 10 subcutaneous melanoma metastases. All samples,
with the exclusion of subcutaneous melanoma metastases,
showed both tumor and normal adjacent epidermis. For each
melanoma case, the patients’ charts were analyzed for age at
diagnosis, sex, site of the tumor, and disease-specific
survival. The median age of patients with melanoma in situ
was 43 years (range, 30-63 years). There were 7 women and
3 men. Tumor site distribution was upper and lower
extremities (6 cases) and trunk (4 cases). These cases were
all superficial spreading melanomas in situ. The median age
of patients with primary invasive malignant melanoma was
52 years (range, 32-81 years). Eleven patients were men,
and 19 patients were women. Tumor site distribution was as
follows: head and neck, 7 patients; upper and lower
extremities, 14 patients; trunk, 8 patients; acral regions,
1 patient. Histopathologic slides were reviewed for the
following parameters: tumor thickness, level, presence of
ulceration, histotype, tumor growth phase (radial versus
vertical). Eight cases were Clark level II; 12 cases were level
III; 8 cases were level IV, and 2 cases were level V. Eleven
cases displayed superficial ulceration. Superficial spreading
Table 1 Distribution of PAR-1 expression in common nevi,
atypical nevi and malignant melanoma (n = 70)
Cases Score
0 1+ 2+ 3+
Common melanocytic nevi (n = 10) 2 2 3 3
Atypical nevi (n = 10) 1 9
In situ melanomas (n = 10) 10
T1 melanomas (n = 10) 10
T2 melanomas (n = 10) 10
T3-T4 melanomas (n = 10) 10
Melanoma metastases (n = 10) 10
Score 0 indicates negative staining; 1+, 1%-20% of positive cells; 2+,
21%-50% of positive cells; 3+, more than 50% of positive cells.
D. Massi et al.678melanoma was the most common histological type (63.3%),
followed by nodular melanoma (13.4%), lentigo maligna
(20%), and acral lentiginous melanoma (3.3%). Seven
invasive melanomas were in radial growth phase, whereas
23 melanomas were in vertical growth phase.
2.2. Immunohistochemistry
Sections, 4 lm in thickness, were cut from tissue blocks
of formalin-fixed paraffin-embedded tissues obtained from
the Department of Human Pathology and Oncology,
University of Florence. Slides were deparaffinized in
Bio-Clear (Bio-Optica, Milan, Italy) and hydrated with
graded ethanol concentrations until distilled water. Tissue
sections were immunostained with mouse thrombin R
(ATAP 2), also designated PAR-1, monoclonal antibody
raised against amino acids 42 to 45 of thrombin receptor of
human origin (Santa Cruz Biotechnology, Santa Cruz,
Calif) and rabbit PAR-2 polyclonal antibody (B5) prepared
as described previously [28]. Unfortunately, none of the
available anti–PAR-2 antibodies (eg, B5, SAM11) visualize
the receptor on Western blot analyses but identify an
unknown non–PAR-2–related epitope (unpublished data).
B5, however, reliably identifies the receptor for immuno-
histochemistry procedures and visualizes PAR-2 from a
number of species, including the human and guinea pig
[29]. Antigen retrieval was routinely performed by
microwave pretreatment (Microwave MicroMED T/T
Mega, Milestone, Bergamo, Italy) in TEC (Tris-EDTA-
citrate buffer pH 7.8) for 35 minutes. Briefly, endogenous
peroxidase activity was blocked by immersing slides in
3.0% hydrogen peroxidase in distilled water for 20 minutes.
After blocking nonspecific antigen with normal horse
serum (UltraVision, LabVision, Fremont, Calif), the sec-
tions were incubated with primary antibody anti–PAR-1
diluted 1:100 in antibody diluent (Ventana Medical
Systems, Tucson, Ariz) for 2 hours at room temperature
and with primary antibody anti–PAR-2 diluted 1:50 and
incubated overnight at 48C. Staining was achieved using a
biotin-conjugated antimouse and antirabbit secondary
antibody (UltraVision) and streptavidin-peroxidase (Ultra-
Vision). The bound antibodies were visualized with
aminoethylcarbazol (AEC, LabVision) as chromogen.
Nuclei were slightly counterstained with Mayer’s hema-
toxylin. Negative controls were performed by substituting
the primary antibodies with a nonimmune serum at the
same concentration. The control sections were treated in
parallel with the samples in the same run.
PAR-1 and PAR-2 immunostained sections were inde-
pendently assessed by 3 observers (D. M., A. F., M. S.). The
results were expressed according to semiquantitative criteria
as negative staining (score 0), 1% to 20% (score 1+), 21% to
50% of positive cells (score 2+), and more than 50% of
positive cells (score 3+). The staining intensity was scored
on a scale as weak, moderate, or strong. The level of
concordance, expressed as percentage of agreement between
the observers, was 92.8% (65/70 specimens). In theremaining 5 cases, unanimous concordance was reached
upon revision and discussion.
2.3. Extraction of RNA from formalin-fixed
paraffin-embedded sections
Total RNA was extracted using a paraffin block RNA
isolation procedure (Ambion, Austin, Tex). Briefly, two
10-lm sections were treated with xylene and incubated for
20 minutes at room temperature. After discarding the
xylene, the sections were washed with absolute ethanol
and then air-dried at room temperature. Each sample was
digested with proteinase K. After total RNA was extracted
using an acid phenol–chloroform solution provided by
manufacturer; to maximize the recovery of RNA, linear
acrylamide was used (Ambion) before precipitation with
isopropanol. After centrifugation and washes with ethanol,
the RNA pellet was air-dried, resuspended in nuclease-free
water, and then analyzed by RPA.
2.4. Ribonuclease protection assay
PAR-1 mRNA levels were evaluated in 35 samples,
including normal skin (n = 3), common melanocytic nevi
(n = 9), atypical nevi (n = 9), and melanomas (n = 9). These
cases had also been examined by immunohistochemistry.
Samples were analyzed by RPA. The total RNA, isolated
from the formalin-fixed paraffin-embedded sections, as
described above, was hybridized overnight to the biotin-
labeled RNA probe, which had been previously synthesized
from the supplied template set (hAngio-1, RiboQuant
multiprobe set; BD Biosciences, San Jose, Calif). Hybrid-
ization was followed by RNase A/T1 and proteinase K
digestion, as previously described [30]. Subsequently, the
products separated for analysis on a denaturing polyacryl-
amide (5%) gel. Gels were then transferred to a positively
charged nylon membrane, using a semidry transfer unit
(Hoefer Pharmacia Biotech, San Francisco, Calif). The
nucleic acids were then immobilized by UV cross-linking.
Nonisotopic detection was performed by BrightStar Bio-
Detect kit (Ambion), following manufacturer’s instructions.
Fig. 1 (A) PAR-1 immunoreactivity in benign common mela-
nocytic nevus. Clusters of nevus cells are negative, whereas PAR-1
is strongly and diffusely expressed in basal and suprabasal
epidermal keratinocytes. (B) Note the positive staining in pericytes
around the vessel wall.
Fig. 2 PAR-1 immunoreactivity in dysplastic melanocytic
nevus. Atypical melanocytes are arranged in nests at the
dermoepidermal junction and show strong and diffuse cytoplasmic
PAR-1 staining. Scattered macrophages and spindle-shaped fibro-
blasts beneath the lesion are also positive.
PARs in melanocytic neoplasia 679PAR-1 and the housekeeping gene L32 transcripts were
identified by the lengths of the respective fragments. Gel
electrophoretic autoradiographs were then quantified using
Sigma Gel analysis software (Jandel Scientific, San Rafael,
CA). PAR-1 values were expressed as a percentage of L32
expressed for each sample (relative area units).2.5. Statistical analysis
Differences between data groups were analyzed using the
nonparametric Kruskal-Wallis analysis of variance followed
by the Bonferroni test. The relationship between PARs
protein expression and clinicopathologic variables was
assessed by the 2-tailed Fisher exact test or by the Pearson
v2 method. A P value of b.05 was considered statistically
significant. Statistical analysis was performed with the SPSS
software, release 9.0 (SPSS Inc, Chicago, Ill).3. Results
3.1. Immunohistochemical analysis
PAR-1 immunohistochemical expression was confined to
the cells’ cytoplasm, with occasional peripheral membrane
pattern, whereas evaluation of PAR-2 immunoreactions
displayed predominantly cytoplasmic with occasional cell
membrane and nuclear staining in normal as well as in
tumor cells.
In normal skin adjacent to melanocytic lesions, PAR-1
was strongly and diffusely expressed in basal and suprabasal
epidermal keratinocytes but not in the granular layer or in
the stratum corneum. PAR-1 positivity was also consistently
observed in the inner root sheath of hair follicles,
Fig. 3 PAR-1 immunoreactivity in malignant melanoma in situ.
PAR-1–positive strikingly atypical melanocytes in single units are
seen at the junction and in pagetoid spread within the epidermis.
Fig. 4 Strong and diffuse PAR-1 staining in neoplastic melano-
cytes in a thin cutaneous melanoma. Note that stromal macro-
phages, fibroblasts, and endothelial cells in the areas of regression
around the tumor are strongly positive.
D. Massi et al.680myoepithelial cells of sweat glands, sebaceous glands, and
blood vessels. Interestingly, immunostaining of blood
vessels showed a stronger labeling in pericytes (vascular
smooth muscle cells) in comparison with endothelial cells.
In some specimens, blood vessels of the superficial capillary
plexus were consistently reactive for PAR-1, whereas
vascular structures more deeply located in the reticular
dermis, far from the tumor, decreased their immunostaining,
indicating a modulation of PAR-1 expression in endothelial
cells. Scattered dermal fibroblasts and macrophages were
also PAR-1–positive. Lymphocytes were PAR-1–negative.
PAR-2 immunoreactivity was predominantly localized to
the basal and suprabasal spinous layers, whereas the upper
superficial layers were unstained. Endothelial cells of
superficial dermal blood vessels also stained positive.
Strong PAR-2 staining was detected throughout adnexal
(hair follicular and eccrine) structures. Stromal fibroblasts,
macrophages, and mast cells stained positive.
Normal epidermal melanocytes generally did not express
either PAR-1 or PAR-2, although in some specimens,
occasional melanocytes showed a faint cytoplasmic posi-
tivity. The immunolabeling in normal epidermal melano-
cytes was found at times difficult to evaluate because of the
presence of a perinuclear clear halo resulting from marked
cytoplasmic retraction.
Table 1 summarizes the results of PAR-1 immunostain-
ing in the whole series of 70 benign and malignant
cutaneous melanocytic lesions categorized according tosemiquantitative criteria. The mean percentages of PAR-1
immunoreactive neoplastic cells in benign and malignant
melanocytic lesions were as follows: common melanocytic
nevi, 35% F 24.61%; atypical melanocytic nevi, 86% F
22.21%; melanoma in situ, 79% F 8.76%; T1 invasive
melanoma, 95% F 9.72%; T2 invasive melanoma, 97% F
9.49%; T3 to T4 invasive melanoma, 94% F 15.78%; and
melanoma metastases, 95% F 7.07%. When all cutaneous
melanoma samples (in situ, invasive, and metastatic) were
grouped together for statistical analysis, the mean percent-
age of PAR-1 expression was 92% F 12.12%.
Overall, common melanocytic nevi (Fig. 1) displayed
significantly less PAR-1 immunostaining in comparison
with atypical nevi and melanoma samples. Most atypical
nevi (Fig. 2) displayed a staining pattern in terms of
distribution similar to that of in situ (Fig. 3), invasive
melanomas (Figs. 4 and 5), and melanoma metastases
(Fig. 6). Regarding the intensity of the immunostaining, in
cutaneous invasive melanoma samples and melanoma
metastases, neoplastic cells were strongly PAR-1–positive,
whereas the intensity of staining was weak in common nevi
and mostly moderate in atypical nevi and in situ melanomas.
However, in some invasive melanomas, we observed that
neoplastic melanocytes in their progressive descent into the
deeper portions of the reticular dermis showed a progressive
decrease in PAR-1 immunoreactivity. PAR-1 staining in-
tensity in stromal fibroblasts and macrophages surrounding
Fig. 5 (A) Intense and diffuse PAR-1 immunoreactivity in thick
invasive cutaneous melanoma. (B) The PAR-1–positive reaction
is evident also in the endothelial cells of microvessels inside
the tumor.
ig. 6 Intense and diffuse cytoplasmic PAR-1 staining in
subcutaneous melanoma metastasis.
Fig. 7 Percentage of PAR-1 cytoplasmic staining in tissue
samples of common melanocytic nevi (CMN), dysplastic nevi
(DN), and malignant melanomas (MM). PAR-1 resulted signifi-
cantly overexpressed in DN and MM in comparison with CMN
(P b .001).
PARs in melanocytic neoplasia 681melanoma cells was not significantly different in compar-
ison with dermal fibroblasts and macrophages adjacent to
normal epidermis.
Statistical analysis showed that PAR-1 was significantly
overexpressed in atypical nevi and melanomas in compar-
ison with common melanocytic nevi (P b .001) (Fig. 7).
Conversely, PAR-2 was strongly and diffusely expressed
by immunohistochemistry in all benign and malignantFmelanocytic lesions, with no statistically significant differ-
ences between nevi and melanomas (Figs. 8 and 9).
Concerning invasive melanomas, no significant correla-
tion was found between PAR-1 or PAR-2 expression and
both disease-specific survival and histopathologic parame-
ters, such as histotype, level, thickness, presence of
regression, and tumor growth phase.
Fig. 8 Strong and diffuse PAR-2 cytoplasmic and nuclear
immunoreactivity in benign common melanocytic nevus. PAR-2
immunoreactivity is also localized to the basal and suprabasal
spinous epidermal layers.
ig. 10 PAR-1 mRNA expression in human melanocytic lesions
y RPA. The blot shown in the figure is one representative of
ultiple blots obtained in independent experiments with similar
sults. PAR-1 mRNA expression values are shown as a percentage
f the housekeeping gene L32 present in each sample (relative area
nits). The data obtained are presented as means F SD. Asterisks
dicate statistically significant (P b .05) differences between
AR-1 mRNA expressed by dysplastic nevi (DN, n = 9) and malig-
ant melanoma (MM, n = 9) versus common melanocytic nevi
MN, n = 9), as judged by Student t test and the Bonferroni
orrection. Results regarding PAR-1 mRNA expression in normal
kin (NS, n = 3) are also reported. DN and MM show higher levels
f PAR-1 mRNA in comparison with CMN. The low PAR-1 mRNA
ignal observed in CMN and NS may be ascribed to the presence of
PAR-1 mRNA within the epidermal and adnexal keratinocytes.
D. Massi et al.6823.2. PAR-1 mRNA expression
RPA analysis showed that PAR-1 mRNA levels were
significantly higher in samples of atypical nevi (28 F 3) and
melanoma (27 F 4) in comparison with common melano-














sno significant differences were found in PAR-1 mRNA
expression between common melanocytic nevi (18 F 3) and
normal skin samples (16 F 2). No significant differences
were observed between PAR-1 mRNA expressed in mela-
noma in situ and invasive melanoma (data not shown). On
the basis of the results of the immunohistochemical study,
the PAR-1 mRNA signal observed in common melanocytic
nevi and controls samples (normal skin) may be ascribed to
the presence of PAR-1 transcript within the epidermal and
adnexal keratinocytes and other PAR-1–positive stromal cells.4. Discussion
Our results indicate that PAR-1 is overexpressed in
dysplastic nevi as well as in primary and metastatic
melanomas in comparison with benign common nevi, thus
supporting a critical role for PAR-1 in the initial phases of
melanocytic tumor transformation and progression. To the
best of our knowledge, this is the first evidence of PAR-1 in
situ expression in human tissue samples of cutaneous
melanocytic nevi and malignant melanoma. PAR-2 protein
was also highly up-regulated in all melanocytic lesions.
However, no significant difference between nevi and
melanomas regarding PAR-2 expression was observed.
These findings support and expand previous observations
PARs in melanocytic neoplasia 683that PAR-1 expression is up-regulated in the human
metastatic cell line A375SM [12]. It has been previously
shown that in human melanoma cells, loss of the transcrip-
tion factor activator protein 2a contributes to PAR-1 up-
regulation, eventually contributing to the acquisition of the
metastatic phenotype [31,32].
The mechanisms by which PAR-1 affects melanoma
development and progression are complex and yet to be
fully clarified. PAR-1 has been demonstrated to modulate
the distribution of cell-surface avb5 integrins promoting
cytoskeletal reorganization, a key step in the processes of
invasion and metastasis [32]. Furthermore, the activation of
PAR-1 contributes to tumor angiogenesis through increased
expression of vascular endothelial growth factor mRNAs
and of functional vascular endothelial growth factor proteins
[32]. PAR-1 also regulates the induction and release of
matrix metalloproteinases, including matrix metalloprotei-
nases 1, 2, 3, and 9, enzymes involved in the proteolytic
degradation of components of the basement membrane and
extracellular matrix [19,33]. PAR-1 has also been attributed
a putative oncogenic role in NIH3T3 cells [34], and we have
previously reported that thrombin down-regulates the
expression of p21waf1/cip1 and up-regulates cyclin D1
mRNA expression, thus contributing to unrestricted prolif-
eration in certain tumor cells lines [35].
In our study, the immunolocalization of PAR-1 and PAR-
2 was largely found in tumor cells and also in epidermal and
adnexal keratinocytes, scattered fibroblasts, macrophages,
and endothelial cells in the adjacent stroma, providing
evidence that both neoplastic and stromal cells are the
sources of PARs in tumor tissues. It is conceivable that, in
the tumor microenvironment, dynamic host-tumor interac-
tions modulate PARs activity in the progression of human
tumors, including malignant melanomas. However, no
significant difference was noted in terms of PAR-1 and
PAR-2 staining intensity in dermal fibroblasts and macro-
phages surrounding melanoma cells in comparison with
those located in proximity of the normal epidermis, far away
from tumor cells. Furthermore, dermal fibroblasts in normal
skin and in benign common melanocytic nevi were also
PAR-1– and PAR-2–positive. These findings are at variance
with previous observations indicating PAR-2 negativity in
normal dermal fibroblasts [36,37] as well as absence of
PAR-1 and PAR-2 immunolabeling in stromal fibroblasts
surrounding normal and breast benign tissues in contrast
with the moderate to strong PAR-1 and PAR-2 staining
observed in the stromal fibroblasts in most breast malignant
tissues [20]. One possible explanation for our findings could
be that resident dermal fibroblasts have acquired a
myofibroblastic phenotype. PAR-1 and PAR-2 marked
expressions have been documented in smooth muscle cells
in a variety of human tissues [37-39].
A major finding of our study is the up-regulation of
PAR-1 expression in atypical so-called dysplastic nevi in
comparison with common melanocytic nevi. This result
suggests that early melanocytic transformation is associatedwith the induction of PAR-1 gene expression and supports
the hypothesis that atypical dysplastic nevi represent not
only a risk factor but a true precursor of cutaneous
melanomas. However, in spite of a wide amount of
epidemiological, clinical, and biologic data accumulated
on this hypothesis, several issues remain unresolved
regarding melanocytic dysplasia: (a) lack of a uniformly
recognized terminology, (b) significant interobserver vari-
ability in the criteria for histopathologic diagnosis, (c)
absence of well-defined dysplastic features associated to
most malignant melanomas, and (d) a limited understanding
of the clinical significance of a diagnosis of dysplasia, in
terms of actual risk and time frame of progression to
melanoma. Further studies aimed to determine the biologic
differences between cells from different stages of melano-
cytic tumor progression are clearly needed to gain more
insight into the tumor biology of cutaneous melanoma.
Results of PAR-1 protein immunohistochemical expres-
sion in melanocytic lesions were corroborated by PAR-1
mRNA study with the RPA technique on formalin-fixed
paraffin-embedded specimens. RPA confirmed immunohis-
tochemical results showing overexpression of PAR-1
mRNA in atypical nevi as well as in malignant melanomas
in comparison with benign common nevi. Maximum mRNA
expression was already detected in dysplastic nevi, as it
remained constant in all the other instances irrespective of
increased level malignancy. In addition, no significant
differences were found in PAR-1 mRNA levels between
common melanocytic nevi and normal skin samples. The
PAR-1 mRNA signal observed in common melanocytic nevi
and normal skin specimens may be ascribed to the presence
of PAR-1 transcript within the epidermal and adnexal
keratinocytes and other PAR-1–positive stromal cells, as
shown by the immunohistochemical study.
The biologic significance of PAR-2 up-regulation in both
benign and malignant melanocytic lesions requires further
investigation. It is known that PAR-2 is implicated in a
broad spectrum of physiopathologic processes, including
cell growth, mitogenesis, and angiogenesis [1,2]. Recently,
considerable interest has been paid to the role of PAR-2 in
cutaneous pigmentation. Indeed, in keratinocyte-melanocyte
cocultures, PAR-2 activation increases the phagocytosis of
melanosomes by keratinocytes and thereby plays a crucial
role in pigmentation [40,41]. Because melanocytic nevi of
different type contain variable melanin granules, we could
speculate that PAR-2 overexpression may be functionally
relevant to nevi pigmentation.
In conclusion, our results demonstrate for the first time
an overexpression of PAR-1 in atypical nevi and malignant
melanoma in comparison with benign common melanocytic
nevi, suggesting that PAR-1 is likely to play a crucial role
in the initial phases of melanoma development as well as
in tumor progression and metastasis. Conversely, the
significance of PAR-2 up-regulation in both benign and
malignant melanocytic lesions represents an intriguing issue
for further research.
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